Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. myarzi12019-03-26T12:52:14+00:00Netazepide| Read More
Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity. myarzi12019-03-26T12:55:35+00:00Netazepide| Read More
The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment. myarzi12019-03-26T13:06:25+00:00Netazepide| Read More
Potential clinical indications for a CCK2 receptor antagonist. myarzi12019-03-26T13:07:10+00:00Netazepide| Read More
Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett’s-like esophagus. myarzi12019-03-26T13:08:07+00:00Netazepide| Read More
Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice. myarzi12019-03-26T13:14:34+00:00Netazepide| Read More
Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1. myarzi12019-03-26T13:15:19+00:00Uncategorized| Read More
Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. myarzi12019-03-26T13:16:38+00:00Netazepide| Read More
Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. myarzi12019-03-26T13:17:41+00:00Netazepide| Read More
Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. myarzi12019-03-26T13:18:13+00:00Netazepide| Read More
